Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631406 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
A Phase 1 study of Ischemic Stroke, sponsored by Gary Steinberg, MD, PhD.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04631406: Active Phase 1 study of Ischemic Stroke, sponsored by Gary Steinberg, MD, PhD.
NCT04631406 is a Phase 1 study of Ischemic Stroke that is active but no longer recruiting, run by Gary Steinberg, MD, PhD. The registered enrollment target is 30 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04631406, a Phase 1 study of Ischemic Stroke, is active but no longer recruiting, sponsored by Gary Steinberg, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Primary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Conditions Studied
Interventions
- BIOLOGICAL Neural Stem Cells
Study Locations (1)
California
- Stanford Health Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 1 |
What the registry record for NCT04631406 still lists
NCT04631406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Neural Stem Cells is the first listed.
NCT04631406 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04631406 about?
NCT04631406 is a clinical study titled "A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)". Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
What is the current status of trial NCT04631406?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-01-04. Estimated completion is 2029-08-31.
What conditions does trial NCT04631406 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT04631406?
The interventions under investigation include: Neural Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04631406?
This trial is sponsored by Gary Steinberg, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04631406 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04631406's enrollment target sits among peer trials
30 52nd of 66 higher than 15 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Verapamil for Neuroprotection in Stroke
RECRUITING · Phase 1
-
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
RECRUITING · Phase 1
-
A Study of NCS-01 in Patients With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 1
-
Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living
COMPLETED · Phase 1
-
The Capillary Index Score Trial
COMPLETED · Phase 1
-
Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI